In addition to PD-L1, high TMB and high MSI have been shown to be useful biomarkers for better immunotherapy response in cancer.[33,34,45] Sed High TMB levels represented highly produced neoantigens, thus drive active antitumor immune responses and ultimately lead to sustained clinical response to immunotherapy. The gene discussed is CD274; the disease is cancer.